Literature DB >> 2513631

Considerations for the prevention of infectious complications in patients with cancer.

P A Pizzo1.   

Abstract

Methods of preventing the infectious complications that occur in patients undergoing therapy for cancer have been the focus of considerable research. Because infections arise from both the endogenous microbial flora and newly acquired organisms and because the pathogens include bacteria, fungi, viruses, and/or parasites and affect a number of different body sites, it has been difficult to conceive of a single or simple method of controlling these multiple infectious etiologies. The suppression or elimination of the host's own microbial flora by the use of various prophylactic antibiotics and the reduction in the patient's acquisition of new organisms by the use of isolation techniques have received the greatest attention. While a number of these approaches (including total protected isolation, nonabsorbable antibiotics, trimethoprim-sulfamethoxazole, selective decontamination, and most recently the quinolones) have appeared to reduce the incidence of infections, few have stood the test of time. The advantages and disadvantages of each of these methods are reviewed, and newer promising areas for current and future investigation are considered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513631     DOI: 10.1093/clinids/11.supplement_7.s1551

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

Review 1.  Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.

Authors:  K L Goa; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

Review 2.  Supportive therapy in management of leukemias.

Authors:  V P Choudhry; N Desai
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

Review 3.  Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part I.

Authors:  C R Thomas; L V Wood; J G Douglas; K J Stelzer; W Koh; R Panicker
Journal:  J Natl Med Assoc       Date:  1994-10       Impact factor: 1.798

Review 4.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Antibacterial effect of bovine milk antibody against Escherichia coli in a mouse indigenous infection model.

Authors:  K Nomoto; Y Matsuoka; K Hayakawa; M Ohwaki; T Kan; Y Yoshikai; K Nomoto
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 6.  Ethical and professional issues in pain technology: a challenge to supportive care.

Authors:  B R Ferrell
Journal:  Support Care Cancer       Date:  1994-01       Impact factor: 3.603

7.  Modulating effect of dietary carbohydrate supplementation on Candida albicans colonization and invasion in a neutropenic mouse model.

Authors:  S L Vargas; C C Patrick; G D Ayers; W T Hughes
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.